<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03235232</url>
  </required_header>
  <id_info>
    <org_study_id>EMS0117</org_study_id>
    <nct_id>NCT03235232</nct_id>
  </id_info>
  <brief_title>BREMEN Eye Drops Versus Combigan and Azopt for Open-angle Glaucoma or Intraocular Hypertension</brief_title>
  <official_title>Randomized Clinical Trial to Compare the Efficacy and Safety of BREMEN Eye Drops Versus Combigan and Azopt in Subjects With Open Angle Glaucoma or Ocular Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the clinical efficacy of the BREMEN eye drops in the
      treatment of primary open-angle glaucoma or intraocular hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2018</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy based in the reduction of intraocular pressure in patients with open-angle glaucoma or hypertension ocular.</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety will be evaluated through the adverse events occurrences</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">266</enrollment>
  <condition>Ocular Hypertension</condition>
  <condition>Primary Open-angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>BREMEN eye drops</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 drop in affected eye(s), each 12 hours for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combigan® and Azopt® concomitantly</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 drop of Combigan® in affected eye(s), each 12 hours for 8 weeks.
1 drop of Azopt® in affected eye(s), each 8 hours for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BREMEN eye drops</intervention_name>
    <description>1 drop in the affected eye(s), twice a day (approximately each 12 hours) for 8 weeks.</description>
    <arm_group_label>BREMEN eye drops</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combigan® and Azopt® concomitantly</intervention_name>
    <description>1 drop of Combigan® in the affected eye(s), twice a day (approximately each 12 hours) for 8 weeks.
1 drop of Azopt® in the affected eye(s), three times a day (approximately each 8 hours) for 8 weeks.</description>
    <arm_group_label>Combigan® and Azopt® concomitantly</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed Consent;

          -  Participants with diagnosis of open-angle glaucoma or hypertension ocular, who needs 3
             or more drugs to control the Intraocular pressure;

          -  Participants who have 20/40 visual acuity or more, in both eyes;

        Exclusion Criteria:

          -  Participants with any clinical significant disease that, after evaluation of the
             investigator, can´t participate in the study;

          -  Participants with active eye disease, which in the investigator opinion may interfere
             in the results of this clinical trial;

          -  Participants presenting previous diagnosis of non-operated cataract, high myopia, high
             astigmatism, pseudoexfoliation and corneal deformities;

          -  Participants who had significant visual loss in the last year;

          -  Participants nonresponders to previous triple combination drug therapy, used in
             concomitance;

          -  Participants with previous ocular or intraocular surgery within six months prior to
             enrollment in the clinical trial;

          -  Participants with history of hypersensitivity to any formula compounds;

          -  Participants presenting contraindications to use of beta-adrenergic antagonists;

          -  Participants diagnosed with uncontrolled cardiovascular disease;

          -  Participants diagnosed with sleep disorders who require medication;

          -  Participants with severe renal insufficiency or hyperchloremic acidosis;

          -  Participants in therapy with monoamine oxidase inhibitors (MAOIs);

          -  Participants who were in use of drugs that can interfere in the evaluation;

          -  Pregnancy or risk of pregnancy and lactating patients;

          -  Alcoholism or illicit drug abuse.

          -  Participation in clinical trial in the year prior to this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Roberto B. Amazonas, MD</last_name>
    <phone>+551938879851</phone>
    <email>pesquisa.clinica@ems.com.br</email>
  </overall_contact>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 27, 2017</study_first_submitted>
  <study_first_submitted_qc>July 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2017</study_first_posted>
  <last_update_submitted>August 3, 2017</last_update_submitted>
  <last_update_submitted_qc>August 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Tetrahydrozoline</mesh_term>
    <mesh_term>Brimonidine Tartrate, Timolol Maleate Drug Combination</mesh_term>
    <mesh_term>Brinzolamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

